logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharma CEO 'buoyed, enthusiastic and proud' as it begins dosing in Phase II MPS trial

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) CEO Paul Rennie speaks to Proactive's Andrew Scott after announcing they've initiated a Phase II clinical trial of subcutaneous injectable Pentosan Polysulphate Sodium (iPPS), in patients with the ultra-rare orphan disease Mucopolysaccharidosis Type 1 (MPS-1). The Phase II trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.94 AUD

ASX:PAR
Market: ASX
Market Cap: $670.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Norman Broadbent secures new loan facility

Norman Broadbent PLC (LON:NBB), the executive search group, has strengthened its balance sheet with a £250,000 six-year CBILS loan. The funds can be drawn at any point before January 16 2021, with a 12 month interest-free period following drawdown, after which an interest rate of 4.75% per...

1 day, 3 hours ago

2 min read